In 2007, drug development in Japan, the world’s second largest pharmaceutical market, exploded six-fold over 2006 and should continue to grow, according to a new CenterWatch report released today.
Japan: Opening the Door to Global Clinical Trials, the fourth in a series of CenterWatch reports on global clinical research markets, takes a look at the reasons for Japan’s dramatic growth, the differences in the country’s approach to clinical research, and government initiatives to attract Big Pharma to conduct simultaneous global clinical trials in Japan.
“New government initiatives have helped to streamline drug review and approval processes, and sponsor companies have responded by including Japan in their global drug development programs more,” said Sara Gambrill, senior editor at CenterWatch and author of the report. “Japan is participating in global drug development at historic levels; however, there is still work to be done there to sustain that growth.”
This is an essential resource for any business seeking to better understand Japan’s clinical trials landscape and what to expect when conducting clinical research there.
To purchase Japan: Opening the Door to Global Clinical Trials, visit the CenterWatch bookstore.